4.1 Therapeutic indications
For use in osteoporosis in post-menopausal women.
Established osteoporosis should have been diagnosed by the following parameters:
i) crush or wedge fractures of the vertebrae
ii) other osteoporotic fractures
iii) established reduction in bone mineral content as measured by accepted BMC measurements.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.
Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).